Published in Women's Health Weekly, May 22nd, 2003
"Due to the high incidence of breast cancer and associated mortality rate, the development of an effective vaccine may be beneficial for the prevention or adjuvant treatment of this malignancy. We have constructed a novel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1, that consists of BCG and expresses a truncated form of MUC1 and human interleukin (IL)-2. In vitro analysis of the BCG-hIL2MUC1 construct confirmed co-expression of MUC1 and human IL-2," scientists in the United States report.
"The ability of BCG-hIL2MUC1 to inhibit breast...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly